Trial Details
AuthorisedBasic Information
| Clinical ID | c3375 |
|---|---|
| Identifier | EUCTR2004-004325-10-GB |
| Trial Title | Evaluate Whether A Short Course Of Once Weekly Risedronate Prevents Bone Loss Following High-Dose Steroid Therapy For An Acute Exacerbation Of Inflammatory Bowel Disease. - Residronate prevening bone loss in IBD during short course steroids. |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | We aim to determine whether Risedronate is effective at preventing acute bone loss associated with a short course of corticosteroid (CS) therapy to treat exacerbations of inflammatory bowel disease (IBD). |
| Interventions | Trade Name: Actonel Once a Week 35mg Pharmaceutical Form: Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: CACIT D3 effervescent granules, 500 mg/440 IU Pharmaceutical Form: |
Participant Information
| Sponsor | United Bristol Healthcare Trust |
|---|---|
| City | - |
| Country/Region | United Kingdom |
Enrollment Criteria
| Sex Requirement | NOT SPECIFIED |
|---|---|
| Age Requirement | - |
Study Design
| Study Type | Interventional clinical trial of medicinal product |
|---|---|
| Phase | Not Available |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |